FTC Eyes Disgorgement In Cephalon Pay-For-Delay Fight

Law360, New York (November 19, 2013, 5:11 PM EST) -- The Federal Trade Commission told a Pennsylvania federal court Monday that the launch of generic versions of Cephalon Inc.’s Provigil did not moot its pay-for-delay suit against the drugmaker, because it can still pursue the billions of dollars Cephalon made while the deals were in place.

Cephalon told a Pennsylvania federal court in late September that the long-running case should be dismissed despite the U.S. Supreme Court's recent ruling allowing pay-for-delay antitrust challenges in FTC v. Actavis because, among other reasons, it was moot now that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.